Scarica l'app Stockscreener
237.95
0.71%
1.67
Dopo l'orario di chiusura:
237.95
Precedente Chiudi:
$236.28
Aprire:
$239.12
Volume 24 ore:
1.12M
Relative Volume:
1.30
Capitalizzazione di mercato:
$15.45B
Reddito:
$4.44B
Utile/perdita netta:
$29.49M
Rapporto P/E:
-12,932.07
EPS:
-0.0184
Flusso di cassa netto:
$1.19B
1 W Prestazione:
-1.16%
1M Prestazione:
-8.56%
6M Prestazione:
+25.85%
1 anno Prestazione:
+86.19%
Intervallo 1D:
$235.66
$239.12
Intervallo di 1 settimana:
$231.59
$244.49
Portata 52W:
$125.78
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
237.95 | 15.45B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals plc (JAZZ) Stock forecasts - uk.finance.yahoo.com
Jazz Pharmaceuticals stock reports record Q2 revenue growth - AD HOC NEWS
JAZZ Reinstated by Goldman Sachs -- Price Target Set at $337 - gurufocus.com
Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating By Investing.com - Investing.com UK
JAZZ Looks 56.8% Overvalued on GF Value™ as Insider Selling Pers - gurufocus.com
Jazz Pharmaceuticals PLC (J7Z.HA) Analyst insights, Price targets and Recommendations - uk.finance.yahoo.com
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance
Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033 - TradingView
Five more years to repay its loans: Jazz Pharmaceuticals (JAZZ) also lowers borrowing margins. - Stock Titan
Jazz Pharmaceuticals (JAZZ) Gains Put Its Valuation Story Back In Focus - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - sg.finance.yahoo.com
Chumi Khurana Recognized by the Asian American Business Development Center in Partnership With America250Jazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals plc (JAZZ) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Jazz Pharmaceuticals stock holds near USD 241.46 as results shape the outlook - AD HOC NEWS
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: A Biotech Powerhouse with 20% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - Yahoo Finance
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - Yahoo Finance
What Makes the Latest Jazz Pharmaceuticals (JAZZ) Story Different? - Kalkine Media
Jazz Pharmaceuticals PLC (JAZZ) Stock Price Target & Forecast - TradingKey
Ajit Baid Joins Jazz Pharmaceuticals as Executive Director, Head of Marketing – EMD Franchise - hrtoday.in
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? - fool.com
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet - Yahoo Finance
Jazz Pharmaceuticals PLC at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences - BioBuzz
Jazz Pharmaceuticals PLC at Deutsche Bank HealthCare Summit Transcript - gurufocus.com
Form 8K Jazz Pharmaceuticals plc For: 15 September By Investing.com - Investing.com South Africa
JAZZ: Oncology and portfolio growth drive raised guidance, with zanidatamab leading future expansion - TradingView
Jazz Pharmaceuticals completes Actio Biosciences acquisition - Investing.com
Jazz Pharmaceuticals completes Actio Biosciences acquisition By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: An 18% Upside Potential Beckons Investors - DirectorsTalk Interviews
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):